Funding - May 21, 2014
Vinnova invests in life science
The Swedish innovation authority will support five new development programs, one of which is focused on widespread diseases and life science. The program, which will receive SEK 100 million in funding, will involve academia, health care and the life science industry. The aim is to make the program a national platform with responsibility for the […]
Business Award - May 21, 2014
SwedenBIO Award to Orexo
Pharmaceutical company Orexo has received this year’s SwedenBIO Award. The award ceremony took place on May 20 during SwedenBIO’s annual meeting. The award was received by Peder Edman, Orexo’s Chief Scientific Officer. The jury’s motivation: “Orexo has during the year succeded in getting Zubsolv both approved and launched in the United States. Swedish life science companies […]
Collaboration - May 20, 2014
New partner for Orexo
Orexo AB announces a new partnership between Orexo US, Inc. and inVentiv Health for the commercialization of Zubsolv in the US. The new partnership agreement replaces existing contracts and will become effective July 1st, 2014 and has a three year term. In the new partnership, Orexo takes the leadership and control of all commercial functions to […]
Uncategorized - May 16, 2014
Breakthrough in cancer research
The origin of each type of cancer is a small group of stem cells that drives the disease development. The gene mutations driving cancer have been tracked for the first time in patients back to a distinct set of cells at the root of cancer – cancer stem cells. The international research team, led by […]
Drug Development Pharma - May 15, 2014
Green light for Oasmia’s production facility
The company’s manufacturing facility in Uppsala, Sweden, has been approved for manufacture of cytostatics by the Swedish Medical Products Agency. The approval concerns manufacture for sales in the EU. With this approval, the Medical Products Agency has confirmed that Oasmia’s manufacture of cytostatics meets the requirements of current Good Manufacturing Practice (cGMP) and Oasmia now has a […]
Drug Development Pharma - May 13, 2014
Kancera applies for new patent
The company has registered a patent application for new substances for cancer treatment that selectively inhibit the enzyme HDAC6. The new patent application is based on HDAC6 inhibitors ability to affect mechanisms both inside of and outside of the cell nucleus. According to an announcement from the company it has been proven that HDAC6 has […]
